Experience of the Spanish Group for Hematopoietic Transplantation (GETMON-GETH) in allogenic Hematopoietic stem cell Transplantation in Philadelphia acute lymphoblastic leukemia.

Autor:	Galán Gómez V; Hemato-Oncología Pediátrica, Hospital Universitario La Paz, Madrid, Spain. Electronic address: victor.galan@salud.madrid.org., de la Fuente Regaño L; Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain. Electronic address: lydia.fuente@estudiante.uam.es., Rodríguez Villa A; Hospital Universitario Reina Sofía, Córdoba, Spain. Electronic address: torovilla@gmail.com., Díaz de Heredia Rubio C; Hospital Universitari Vall d'Hebron, Barcelona, Spain. Electronic address: crdiaz@vhebron.net., González Vicent M; Hospital Infantil Universitario Niño Jesús, Madrid, Spain. Electronic address: mgvicent@salud.madrid.org., Badell Serra I; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Electronic address: ibadell@santpau.cat., María Fernández J; Hemato-Oncología Pediátrica, Hospital Universitario y Politécnico La Fe, Valencia, Spain. Electronic address: fernandez_jma@gva.es., Isabel Pascual Martínez A; Hemato-Oncología Pediátrica, Hospital Materno Infantil Carlos Haya, Málaga, Spain. Electronic address: Pascualmartinez5@hotmail.com., María Pérez Hurtado J; Hemato-Oncología Pediátrica, Hospital Universitario Virgen del Rocío, Sevilla, Spain. Electronic address: mendozaj.perez.sspa@juntadeandalucia.es., López Duarte M; Hemato-Oncología Pediátrica, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain. Electronic address: monica.lopez@scsalud.es., Soledad Maldonado Regalado M; Hemato-Oncología Pediátrica, Hospital Universitario Ramón y Cajal, Madrid, Spain. Electronic address: mariasoledad.maldonado@salud.madrid.org., Pérez-Martínez A; Hemato-Oncología Pediátrica, Hospital Universitario La Paz, Madrid, Spain. Electronic address: aperezmartinez@salud.madrid.org.
Jazyk:	angličtina
Zdroj:	Anales de pediatria [An Pediatr (Engl Ed)] 2022 Apr; Vol. 96 (4), pp. 309-318. Date of Electronic Publication: 2022 May 03.
DOI:	10.1016/j.anpede.2021.02.016
Abstrakt:	Introduction: Outcomes in patients diagnosed of acute lymphoblastic leukemia with Philadelphia chromosome (Ph-ALL) remains unfavourable compared to other subtypes of acute lymphoblastic leukemia despite improvements in drug treatments as well as advances in hematopoietic stem cell transplantation (HSCT). Patients and Methods: The role of allogeneic HSCT in Ph-ALL patients has been analysed through a multicentric study where data belonging to 70 patients diagnosed of this entity in different centers that received HSCT between years 1998 and 2014, were reported by the Grupo Español de Trasplante Hematopoyético (GETH). Results: The performance of HSCT from year 2004, in first complete remission (CR) status with thymoglobulin (ATG) based conditioning had a favorable impact on overall survival (OS). HSTC performance from year 2004, in first CR with ATG-based conditioning in addition to acute graft versus host disease (aGvHD) development, increased event free survival (EFS). Treatment with imatinib as well as undetectable minimal residual disease (MRD) prior to HSCT, combined with aGvHD, reduced risk of relapse (RR). Patient age less than 10 years when HSCT, first CR and ATG-based conditioning were associated to a lower transplant related mortality (TRM). Conclusions: Patients that could achieve first CR that also received ATG-based conditioning had a better OS and EFS, so HSCT should be considered for this group of patients. (Copyright © 2022 Asociación Española de Pediatría. Published by Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu